Benzinga · Sep 3, 2026
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.
ZY
NASDAQ · ZYME
Zymeworks Inc.
Healthcare · Biotechnology
$26.44
Down-$0.28 (-1.07%)
Updated Sep 11, 2026, 5:15 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.88B
- P/E ratio
- -0.1
- Dividend yield
- 0.00%
- 52-week range
- $21.52 – $31.34
- Volume
- 585.29K
- Avg. volume
- 1.14M
Price performance
ZYME price history
1M range · 20 trading sessions · Daily adjusted prices
ZYME closed at $26.44 after 20 trading sessions, up 2.62% for the selected period.
- Last close
- $26.44
- Period change
- +2.62%
- Period low
- $25.12
- Period high
- $31.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $26.81 | $27.04 | $26.39 | $26.435 | 585.29K |
| Sep 9, 2026 | $27.81 | $28.09 | $27.08 | $27.15 | 396.03K |
| Sep 8, 2026 | $28.93 | $28.93 | $28.07 | $28.11 | 443.27K |
| Sep 4, 2026 | $29.81 | $29.99 | $29.0883 | $29.19 | 476.6K |
| Sep 3, 2026 | $31.34 | $31.34 | $29.59 | $29.90 | 790.94K |
| Sep 2, 2026 | $30.00 | $31.17 | $30.00 | $31.05 | 808.1K |
| Sep 1, 2026 | $29.32 | $29.90 | $29.075 | $29.67 | 483.06K |
| Aug 31, 2026 | $28.06 | $29.70 | $27.81 | $29.41 | 716.49K |
| Aug 28, 2026 | $28.91 | $28.91 | $28.18 | $28.27 | 542.19K |
| Aug 27, 2026 | $29.33 | $29.58 | $28.53 | $29.01 | 625.16K |
| Aug 26, 2026 | $27.56 | $30.62 | $27.48 | $29.305 | 1.22M |
| Aug 25, 2026 | $28.86 | $30.50 | $25.6095 | $27.47 | 2.08M |
| Aug 24, 2026 | $28.68 | $28.83 | $27.01 | $28.77 | 824.55K |
| Aug 21, 2026 | $26.97 | $28.74 | $26.77 | $28.67 | 836.38K |
| Aug 20, 2026 | $27.08 | $27.16 | $26.235 | $26.57 | 498.75K |
| Aug 19, 2026 | $27.12 | $27.8326 | $26.365 | $27.21 | 845.21K |
| Aug 18, 2026 | $25.35 | $26.35 | $25.31 | $26.07 | 650.17K |
| Aug 17, 2026 | $25.01 | $25.80 | $24.94 | $25.31 | 442.4K |
| Aug 14, 2026 | $25.62 | $25.73 | $24.89 | $25.12 | 332.6K |
| Aug 13, 2026 | $25.27 | $25.99 | $24.96 | $25.76 | 664.68K |
Latest ZYME news
The latest Smart Investors Daily articles mentioning ZYME.
Stock researchCompany · Overview
ZYME research
Overview
Company profile and research snapshot.
Company profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | JP Morgan | Overweight | — |
| Aug 26, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 26, 2026 | Citigroup | Buy | — |
| Aug 26, 2026 | Citizens | Market Outperform | — |
| Aug 10, 2026 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 28, 2026
Zymeworks (ZYME), What Is Behind The Renewed Attention?
Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision might imply for future revenue potential. Against this backdrop, Zymeworks has seen momentum build, with a 30 day share price return of 28.31% and a 90 day gain of 15.44%. The 1 year total shareholder return of 95.49% and very large 3 year total...
Yahoo · Aug 28, 2026
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?
Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recent gains and optimism around its HER2-targeting therapy are now being weighed against signals that point to limited valuation cushion at today’s levels. Zymeworks has returned about 301% over the past three years, which puts extra focus on whether recent gains already reflect much of the good...
SeekingAlpha · Aug 27, 2026
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Zymeworks' zanidatamabâs first-line HER2+ gastroesophageal cancer approval expands the eligible patient population. Find out why ZYME stock is a buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
